RedHill Biopharma (RDHL) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
RedHill Biopharma Ltd. has mutually agreed with Cosmo Technologies Ltd. to terminate their exclusive U.S. license agreement for Aemcolo, a traveler’s diarrhea treatment. The termination will come into effect on October 8, 2024, resulting in all rights returning to Cosmo, and RedHill ceasing its commercialization of the drug. RedHill, a specialty biopharmaceutical company, is known for its focus on gastrointestinal and infectious diseases, with several late-stage development programs underway.
For further insights into RDHL stock, check out TipRanks’ Stock Analysis page.